Immunotherapy plus standard treatment for rectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial is testing whether adding the immunotherapy drug tislelizumab to standard total neoadjuvant treatment (chemotherapy and radiation before surgery) can improve outcomes for people with locally advanced rectal cancer. The goal is to see if the combination helps shrink the tumor more than standard treatment alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have newly diagnosed, locally advanced rectal cancer (tumor within 12 cm of the anal opening) that hasn't spread to other organs.
- You have not had any prior chemotherapy, radiation, immunotherapy, or surgery for this cancer or any radiation to the pelvis.
- You are in generally good health (ECOG score 0 or 1) and your blood counts, kidney, and liver function are within certain limits.
- You can swallow tablets and are willing to use effective contraception (if applicable) for the study period.
- You do not have a history of autoimmune disease (except well-controlled thyroid, type 1 diabetes, or skin conditions), active hepatitis or HIV, or another cancer in the past 2 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests adding immunotherapy to standard radiation and chemotherapy for patients with locally advanced rectal cancer. The goal is to see if a personalized approach improves outcomes while sparing more normal tissue.
This trial tests a combination of short course radiation therapy, chemotherapy, and two immunotherapy drugs for people with a specific type of rectal cancer that is locally advanced but can still be removed by surgery. It may offer a more effective treatment option for those with mismatch repair proficient (pMMR) or microsatellite stable (MSS) tumors.
This trial tests combining immunotherapy with standard chemotherapy and radiation before surgery for locally advanced rectal cancer. It aims to see if this approach can improve outcomes for patients whose tumors have certain genetic features (pMMR or MSS).
This trial tests whether giving a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) along with chemotherapy and bevacizumab before surgery can shrink rectal tumors and improve outcomes. It is designed for people with locally advanced rectal cancer that has not spread to distant organs, and the treatment is given as a first step before the main surgery.
This trial tests a short course of radiation with chemotherapy, targeted therapy, and immunotherapy before surgery for locally advanced rectal cancer. It aims to shrink the tumor and improve outcomes.
This trial tests whether adding an immunotherapy drug (dostarlimab) to standard chemotherapy after the usual chemoradiation helps treat locally advanced rectal cancer better than chemotherapy alone. Immunotherapy helps your immune system fight cancer cells, and may improve outcomes.
Hear when a new Locally Advanced Rectal Cancer (LARC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.